⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EVAX News
Evaxion A/S American Depositary Share
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
globenewswire.com
EVAX
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
globenewswire.com
EVAX
Evaxion expands AI-Immunology™ platform with automated vaccine design module
globenewswire.com
EVAX
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
globenewswire.com
EVAX
Evaxion out-licenses vaccine candidate EVX-B3 to MSD
globenewswire.com
EVAX